AlloVir and Kalaris Therapeutics announce all-stock merger to focus on retinal diseases
After closing, the combined company is expected to operate under the name Kalaris Therapeutics, Inc.
Related Articles
Luxated Globe at Birth—A Vision-Threatening Emergency
This case report discusses a diagnosis of globe luxation at birth resulting from instrumental vaginal delivery.
Week in Review: Retinal Morphology and the Menstrual Cycle, Stem Cell–Derived Treatment for LSCD, Air Pollution and Eye Clinic Visits
Changes in retinal morphology are seen across the menstrual cycle, patients with limbal stem cell deficiency may soon benefit from a new corneal construct, and…
Adverum Biotechnologies announces topline 52-week results from LUNA Phase 2 trial and 4-year OPTIC results
Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease who required frequent anti-VEGF injections before…
Ocugen Reports Preliminary Data
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Ocular Oncology Rotation – American Academy of Ophthalmology
This course was designed by members of the Academy’s Committee for Resident Education to supplement learning in the field of ocular oncology.
Subconjunctival Mass 30 Years After Melanoma Resection
A 70-year-old male is referred for evaluation of a conjunctival mass in the right eye, which has grown slowly over 27 years. Examination reveals a…
Long-Term Blood Pressure Variability and Visual Field Progression in Glaucoma
This cohort study assesses the association between variability in blood pressure and visual field progression in patients with suspected or confirmed glaucoma.
Innovation and the clinician-scientist
A discussion with Shigeru Kinoshita, MD, PhD; and Edward J. Holland, MD.
A Survey of Current Gonioscopy Practice in the United… : Journal of Glaucoma
bjective: Gonioscopy is an important general skill learned and practiced by all grades of ophthalmologists. The aim of this study is to discover the general…
FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry eye
A PDUFA decision date of April 2, 2025 has been assigned